Peapod Lane Capital’s Metagenomi Therapeutics MGX Stock Holding History

Peapod Lane Capital’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$683K	Buy	516,761 +19,108	+4%	+$29.7K	0.56%	58
2025 Q4	$806K	Sell	497,653 -16,162	-3%	-$35K	0.69%	50
2025 Q3	$1.22M	Buy	513,815 +5,706	+1%	+$11.6K	1.09%	42
2025 Q2	$752K	Buy	508,109 +155,652	+44%	+$244K	0.75%	47
2025 Q1	$479K	Buy	352,457 +1,244	+0.4%	+$2.96K	0.54%	55
2024 Q4	$1.27M	Buy	+351,213	New	+$847K	1.26%	34

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Peapod Lane Capital's MGX Position: Q1 2026 in Review

Peapod Lane Capital increased its Metagenomi Therapeutics (MGX) stake by 3.8% in Q1 2026, buying an estimated $29.7K and bringing the position to 516,761 shares worth $683K. The position accounts for 0.56% of the portfolio, ranked #58.

Peapod Lane Capital first reported a position in MGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.27M in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Peapod Lane Capital held 516,761 shares of Metagenomi Therapeutics worth $683K as of Q1 2026.
Peapod Lane Capital bought 19,108 Metagenomi Therapeutics shares in Q1 2026, an estimated $29.7K.
Metagenomi Therapeutics made up 0.56% of Peapod Lane Capital's portfolio in Q1 2026, its #58 holding.
Peapod Lane Capital first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 6 quarters since.
Peapod Lane Capital's Metagenomi Therapeutics position peaked at $1.27M in Q4 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Peapod Lane Capital's 13F filing for Q1 2026, filed 4 May 2026.